GlassScriptPhysician profile
Leon Pappas
NPI 1164910519
$5,652.85
in general payments reported to CMS, 2019-2025
8 companies · $5,471 in 2025
The $5,471 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $182 · 2025: $5,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,720 · Food and Beverage: $543 · Travel and Lodging: $300 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,720.00 |
| Food and Beverage | $542.56 |
| Travel and Lodging | $300.30 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,967.58 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,052.72 | 2025 | Fruzaqla |
| Astrazeneca Pharmaceuticals LP | $204.79 | 2024-2025 | Imfinzi, Imjudo |
| Astrazeneca Uk Limited | $134.99 | 2025 | |
| Beone Medicines USA, INC. | $134.78 | 2025 | |
| Pfizer INC. | $89.99 | 2024 | |
| Genentech USA, INC. | $68.00 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Pappas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.